These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17519460)

  • 21. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
    Matlock A; Allan N; Wills B; Kang C; Leikin JB
    Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Con: The black box warning on droperidol should not be removed (but should be clarified!).
    Ludwin DB; Shafer SL
    Anesth Analg; 2008 May; 106(5):1418-20. PubMed ID: 18420855
    [No Abstract]   [Full Text] [Related]  

  • 23. The black box warning.
    Abourjaily HM; Rosenberg M
    J Mass Dent Soc; 2002; 51(3):54-6. PubMed ID: 12380043
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA use of the black box warning: time for reevaluation as a safety tool.
    Liang BA
    J Clin Anesth; 2002 Dec; 14(8):561-3. PubMed ID: 12565112
    [No Abstract]   [Full Text] [Related]  

  • 25. News flash: Old Mother Hubbard reports the cupboard is bare...time for the FDA to let droperidol out of the (black) box.
    Faine B; Hogrefe C
    Ann Pharmacother; 2012 Sep; 46(9):1259-61. PubMed ID: 22828973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reintegrating droperidol into emergency medicine practice.
    Mattson A; Friend K; Brown CS; Cabrera D
    Am J Health Syst Pharm; 2020 Oct; 77(22):1838-1845. PubMed ID: 32839811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Droperidol's effect on QT interval.
    Martinez JB; Moos DD; Dahlen LL
    J Perianesth Nurs; 2006 Apr; 21(2):82-7. PubMed ID: 16600828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
    Lawrence KR; Nasraway SA
    Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-generation Antipsychotics Are Often Prescribed in the Emergency Department but Are Often Not Administered with Adjunctive Medications.
    Campillo A; Castillo E; Vilke GM; Hopper A; Ryan V; Wilson MP
    J Emerg Med; 2015 Dec; 49(6):901-6. PubMed ID: 26433424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of droperidol in a United States emergency department.
    Gaw CM; Cabrera D; Bellolio F; Mattson AE; Lohse CM; Jeffery MM
    Am J Emerg Med; 2020 Jul; 38(7):1310-1314. PubMed ID: 31831345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified?
    Gan TJ; White PF; Scuderi PE; Watcha MF; Kovac A
    Anesthesiology; 2002 Jul; 97(1):287. PubMed ID: 12131145
    [No Abstract]   [Full Text] [Related]  

  • 32. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
    Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
    J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of the safety of 5-HT3 antagonists with dexamethasone or droperidol for prevention of PONV.
    Leslie JB; Gan TJ
    Ann Pharmacother; 2006 May; 40(5):856-72. PubMed ID: 16670360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Droperidol and dolasetron alone or in combination for prevention of postoperative nausea and vomiting after vitrectomy.
    Eberhart LH; Morin AM; Hoerle S; Wulf H; Geldner G
    Ophthalmology; 2004 Aug; 111(8):1569-75. PubMed ID: 15288990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sevoflurane causes greater QTc interval prolongation in elderly patients than in younger patients.
    Nakao S; Hatano K; Sumi C; Masuzawa M; Sakamoto S; Ikeda S; Shingu K
    Anesth Analg; 2010 Mar; 110(3):775-9. PubMed ID: 20185656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reviewing case reports and the droperidol warning: FDA response.
    Chang N; Simone A; Schultheis L; Rappaport B
    Anesth Analg; 2003 Nov; 97(5):1542. PubMed ID: 14570686
    [No Abstract]   [Full Text] [Related]  

  • 37. Antipsychotic drug use since the FDA black box warning: survey of nursing home policies.
    Lester P; Kohen I; Stefanacci RG; Feuerman M
    J Am Med Dir Assoc; 2011 Oct; 12(8):573-577. PubMed ID: 21450177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA advisory panel discusses droperidol concerns.
    Young D
    Am J Health Syst Pharm; 2004 Feb; 61(3):219-20, 222. PubMed ID: 14986550
    [No Abstract]   [Full Text] [Related]  

  • 39. "Black box" warning on droperidol: report of the FDA convened expert panel.
    Gan TJ
    Anesth Analg; 2004 Jun; 98(6):1809. PubMed ID: 15155354
    [No Abstract]   [Full Text] [Related]  

  • 40. The effects of the FDA warning on the use of droperidol by u.s. Emergency physicians.
    Richards JR; Weiss SJ; Bretz SW; Schneir AB; Rinetti D; Derlet RW
    Cal J Emerg Med; 2003 Jan; 4(1):3-9. PubMed ID: 20852711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.